Management Team

Dr. Pilkiewicz is our President and Chief Executive Officer. He formed Adgero Biopharmaceuticals, Inc. for the purpose of acquiring biotech and pharmaceutical technologies with high commercial content. Adgero acquired REM-001 Therapy and all the assets associated with it at the end of 2012.

Dr. Pilkiewicz was the Principal at Pilkiewicz Consulting and Development where he provided business and technical consulting services, primarily to the pharmaceutical and biotechnology industry and venture and early stage investment groups focused on those areas. Prior to this, he was the President and Chief Executive Officer of CellXplore, Inc., a biotechnology company focused on the treatment and diagnosis of breast cancer. Earlier, Dr. Pilkiewicz was the President and Chief Executive Officer of Transave, Inc., a pharmaceutical company that he founded following his invention of Transave, Inc.'s inhalation drug delivery technology for treating serious pulmonary diseases. Transave was acquired by Insmed in 2010 in a deal valued at over $120 million, and its lead product, Arykace, developed with the inhalation drug delivery technology invented by Dr. Pilkiewicz, is currently awaiting approval.

Previously, Dr. Pilkiewicz served as Vice President of Research & Development at The Liposome Company, Inc. where his team developed a number of commercial liposomal products including its lead products: Myocet® for metastatic breast cancer, and Abelcet® for serious fungal infections in immunocompromised patients like those with cancer. The Liposome Company was acquired by Elan in a deal valued at over $575 million. Dr. Pilkiewicz has served as a member of the board of directors of CellXplore, Inc., Charis Pharmaceutical, Inc., Transave, Inc., and OncoTherapeutics, Inc.. He is currently serving on the Life Sciences Advisory Board for the New Jersey Economic Development Authority.

Dr. Pilkiewicz earned a B.S. in chemistry from Saint Peter's University, an M.S. in organic chemistry from Rutgers University and has a Ph.D. in organic chemistry from Rutgers University. He was a Postdoctoral Research Fellow at Columbia University in organic chemistry.

Dr. Garzon is our Chief Medical Officer. He has more than 30 years of international clinical experience in the development and approval of new drugs in oncology, including breast cancer therapies, while at several leading pharmaceutical and biotechnology companies in the U.S. and European Union.

Dr. Garzon joins the Adgero team having recently served as Senior Vice President of Clinical Development at Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) where he led the clinical development for Actinium's lead oncology product and managed interactions and discussions with the FDA. Prior to his time at Actinium, from 2010 - 2015, he served as the Senior Director of Oncology, Product Creation Unit of EISAI Inc., where he was the International Program Leader for Halaven(r) (Eribulin), which was successfully submitted for registration with the EMA for advanced breast cancer and was subsequently approved in the U.S. as well. From 2006 - 2010, Dr. Garzon served as the Director of Oncology Global Clinical Research at Bristol-Myers Squibb USA, where his responsibilities included leading the FDA, EMA and Latin America Regulatory Agency submissions for Sprycel(r) (dasatinib) in advanced chronic myelogenous leukemia ("CML"), which resulted in the approval of Sprycel for the treatment of resistant and/or intolerant CML patients. His prior experience also includes European Senior Director of Oncology at Chiron Biopharmaceuticals, European Medical Director of Cell Therapeutics Ltd, and a consultant for clinical research at a number of European companies.

Dr. Garzon received his M.D. from Cordoba National University in Argentina, completed his Residency in Clinical Medicine and Assistant of the Oncology Department at the Aeronautic Hospital in Cordoba, Argentina, and completed his training in Clinical Oncology at the Department of Chemotherapy of Leon Berard Cancer Center in Lyon, France. Additionally, he holds a Ph.D. in Medicine from Ruprecht Karl University in Heidelberg, Germany.

Ms. Maida is our Chief Financial Officer and Vice President of Finance. She has more than 20 years of industry experience and is widely versed in strategic financial planning, business intelligence, corporate strategy, M&A and investor relations. Over the course of her career, she has implemented strategic business plans, raised funding and has successfully executed financial and corporate strategies for both public and private companies.

Ms. Maida joins the Adgero team from her most recent role as Chief Financial Officer of Signum Biosciences, Inc., a biotechnology company focused on the development of therapeutic agents for Alzheimer's, Parkinson's and other neurodegenerative diseases. While at Signum Biosciences, Inc., she also served as the CFO for its subsidiaries, Signum Dermalogix, Inc. and Signum Nutralogix, Inc. Prior to that, Ms. Maida served as the CFO of Abeille Pharmaceuticals, Inc., a biotechnology company focusing on the reformulation of products coming off patent in the area of supportive cancer care and diabetes. Ms. Maida also served as CFO and Chief Accounting Officer at Physiome Sciences, Inc., a biotechnology company focusing on software development for modeling of various cells, tissues and organs, which was merged with Predix Pharmaceuticals, Inc. Prior to that, she served as Vice President of Finance and Chief Accounting Officer of Cytogen Corporation, an oncology focused biotechnologycompany. Other positions Ms. Maida has held include Chief Financial and Information Officer at Mustard Seed, a behavioral healthcare company and Director of Finance at The Liposome Company, Inc. (now part of Elan), a biotechnology company.

Dr. Rychnovsky is our Vice President of Operations and Product Development. He is experienced in all aspects of Adgero's photodynamic therapy and, since 2012, Dr. Rychnovsky has worked with Dr. Pilkiewicz to develop Adgero’s business strategy and plans for the development and commercialization of REM-001.

Dr. Rychnovsky is a former consultant to St. Cloud Investments where he was responsible for the portfolio of assets acquired from Miravant Medical Technologies (“Miravant”), the Company that originally developed Adgero's core technology. Prior to this he was the Cardiovascular Program Manager at Miravant, where he invented key elements of Miravant’s cardiovascular technology. Dr. Rychnovsky also served as the Director of Systems and Engineering at Miravant where he managed the team responsible for development of Miravant’s photodynamic therapy (PDT) light delivery technology. During his time at Miravant, Dr. Rychnovsky was involved in new product development for its cancer, ophthalmology and cardiovascular programs, including clinical development of REM-001 and related PDT technology.

Dr. Rychnovsky earned a B.S. in electrical engineering from Iowa State University, an M.S. in electrical engineering from the University of Minnesota and has a Ph.D. in photonics from the University of Iowa.

Ms. Edgerly-Pflug is our Vice President of Manufacturing Operations and Quality Control. She has extensive experience in product and process development and scale-up from bench to commercial process having over 25 years' in manufacturing and quality control in the biotechnology-pharmaceutical industry.

Ms. Edgerly-Pflug has worked on the development and commercialization of a number of complex pharmaceuticals and biologicals with a wide range of formulations and routes of administration. She has extensive experience in product and process development and scale-up from bench to commercial process, all areas of good manufacturing practice (GMP) compliance, and has developed and implemented quality management systems and improved pre-existing quality systems. During her time at Pflug BioPharm Solutions, she provided strategic direction and implementation to clients in the areas of quality assurance, new technologies, new products and lifecycle initiatives. Ms. Edgerly-Pflug served at Insmed Incorporated, formerly Transave Inc., as VP of Technical Operations and Chemistry, Manufacturing and Controls, and served as the Director of Manufacturing at Ovation Pharmaceuticals Inc., currently Recordati Rare Diseases. Earlier in her career, Laura served as Senior Director of Global Pharmaceutical Development at Biomira, where she was accountable for all staff and activities focused on the development of liposome-based cancer vaccines, proteins, and peptides in support of pre-clinical and clinical studies. Following her initial industrial position as a chemist at Colgate-Palmolive, Laura rose to the rank of Scientist at The Liposome Company where she developed the validation process for the company's lead commercial product Abelcet®.

Ms. Edgerly-Pflug earned a B.S. in Chemistry from Kean College of New Jersey.